Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (2240)	12/6/2000 4:17:39 PM
From: Biomaven	Respond to of 52153

ij, Yes, I like NBIX as a long-term play at these levels. Promising pipeline, smart people. Some patience will likely be required, though. Their CRF rapid-acting depression program is a potential blockbuster - their own CRF1 compound should enter the clinic next year, with the Janssen-partnered backup compound hot on their tail. (The original Janssen compound showed excellent efficacy in a small, open-label trial, but produced some reversible liver enzyme elevations in a few patients.) Also interesting sleep, diabetes and obesity programs, not to mention their glioma and MS trials. The sleep program is the furthest advanced of their products, but will likely come in behind SEPR's zopiclone ICE in terms of timing. Peter